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Abstract: Rosmarinic acid is a water-soluble ester of caffeic acid and 3,4-dihydroxyphenyllactic acids, and is mainly
found in plant species including Boraginaceae and Lamiaceae. In this research, we determined the inhibition property of
rosmarinic acid on carbonic anhydrase isoenzymes I and II (hCA I and II) purified from human erythrocytes by using
Sepharose-4B affinity column chromatography. hCA I and II isoenzymes were obtained with a yield of 57.9% and 67.2%
and 76.5- and 509.3-fold purification of each isoenzyme, respectively. In order to show the purity of the isoenzymes,
SDS-PAGE was performed and one band was observed. In vitro inhibition of both hCA I and II isoenzymes by rosmarinic
acid using CO 2 -esterase activity gave Ki values of 86.0 µ M and 57.0 µ M, respectively.
Key words: Carbonic anhydrase I, carbonic anhydrase II, rosmarinic acid, enzyme purification, enzyme inhibition

1. Introduction
Enzymes, biological molecules responsible for thousands of metabolic processes, are synthesized by living cells
and speed up in chemical reactions during the metabolism of living organisms. 1 Carbonic anhydrases (CAs;
Carbonate hydrolyase, E.C.: 4.2.1.1) are metalloenzymes widespread in most living organisms and systematized
by 5 historical irrelevant gene families: the α -, β -, γ -, δ - and ζ -CA. 2 The α -CA is found in mammals, β -CA
is found in plants and some prokaryotes, and γ -CA exists only in archaea bacteria. Two other rare classes
(δ -CA and ζ -CA) are similar to the β -CA class found in diatoms. 3 The 3 main classes ( α -, β -, and γ -) of
CA are structurally discrete and are thought to have evolved independently, possibly as a result of convergent
evolution. 3 CA enzyme greatly increases the rate of the reaction between 10 4 and 10 6 reactions per second.
Most CAs contain a zinc ion in their active site. The α -, β -, and δ -CAs contain a Zn 2+ ion at the active site.
On the other hand, the γ -CAs are likely Fe 2+ enzymes, while the metal ion is generally replaced by Cd in the
ζ -CAs. 2 CA was first isolated from bovine erythrocytes in 1933. The discovery of this CA in erythrocytes was
over 80 years ago. 4 Subsequently, it was purified and characterized from many different plant and animal tissues.
Mammalian CA’s molecular mass is about 30 kDa. CA catalyzes the conversion of carbon dioxide (CO 2 ) to
+
bicarbonate (HCO −
3 ) ion and proton (H ). CA has a ping-pong catalytic mechanism for both hydration and
5
dehydration of CO 2 and HCO −
3 .

Enzyme ∼ Zn2+ −OH − +CO2 ⇐⇒ Enzyme ∼ Zn2+ −HCO3
Enzyme ∼ Zn2+ −HCO3 + H2 O ⇐⇒ Enzyme ∼ Zn2+ −H2 O + HCO3
∗ Correspondence:
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Enzyme ∼ Zn2+ −H2 O + B ⇐⇒ Enzyme ∼ Zn2+ −OH +BH +
In the hydration direction, primarily, a CO 2 molecule binds to the active site of CA. The second step is the
nucleophilic attack of a Zn 2+ -bound hydroxide ion (OH − ) on CO 2 with the subsequent formation of HCO −
3 .
Then HCO −
3 is displaced from the active site by a H 2 O molecule. As can be seen in the Scheme, in the
next step, Zn 2+ –OH − is formed as a result of H + transfer from Zn 2+ –H 2 O generated in step one to the
bulk solvent. 5 A ∼ Zn 2+ –OH − species of the enzyme is the catalytically active species. It acts as a powerful
nucleophile on the CO 2 molecule bound in a hydrophobic pocket nearby. 6−8 Then ∼ Zn 2+ –OH − is formed
from H 2 O coordinated to the Zn 2+ , which exists at the bottom of the active site cavity of CA.
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Scheme. Catalytic and inhibition mechanisms of carbonic anhydrases.

The molecular characteristics of CA across the plant and animal kingdoms are similar. In the red blood
cell, this enzyme is necessary to facilitate the transport of CO 2 out of the body. 9
The human CA isoenzymes belong to the α -class. So far, 16 CA isozymes have been found and identified.
These isoenzymes have distinct molecular properties, oligomeric regulation, and cellular locality; different
distribution in living tissues and organs; different expression levels; and varied kinetic features and response to
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unlike classes of inhibitor. As a result, in some studies recently, CA isozymes have gained an important role
and become an interesting target for designing potent inhibitors or activators with biochemical and biomedical
applications. 2
hCA I is found in the human erythrocyte cell. hCA II is the most studied and analyzed CA isoenzyme.
It is purified from human blood when the amount of 2 mg g −1 of hemoglobin is calculated and this value is less
than that of hCA I. 10 The eye lens, cornea, and ciliary epithelium have high hCA II and IV. hCA II isoenzymes
are still in the renal cortex membrane bound and reabsorption of Na + and H 2 O is provided. When there is
deficiency of hCA II, bone calcification, kidney stone formation, and calcification occur. 11
In skeletal muscle, hCA III isoenzyme was found and this isoenzyme has a very important role in the
balance of lactic acid/lactate as studies have shown. hCA VI and hCA IV isoenzymes are 2 signal sequences that
enable the signal to reach the target tissues and organs. hCA IV isoenzyme is a membrane-bound enzyme and
is bound with the kidney membrane. Moreover, it was found bound with the some epithelial and plasma cells
membranes in the lung capillary surfaces. On the other hand, hCA V isoenzyme is located in the mitochondria
of some tissues. hCA VI isoenzyme is an enzyme released from the salivary glands. In addition, it has been
isolated from human saliva and sputum. hCA VII isoenzyme allows saliva secretion of bicarbonate (HCO −
3 ) . CA
VIII enzyme obtained from rat brain was discovered in a cDNA library. Moreover, human cDNA homologues of
the isoenzymes were identified and amino acid sequences determined. 3 In some physiological characteristics of
CA, it was demonstrated that the CA isoenzymes had important roles. As a result, CA isozymes have become
an interesting scientific field for the design of inhibitors or activators with biomedical applications recently. 2
Phenols have been studied in detail as inhibitors of CA that contain zinc ion. 12−14 Many natural and
synthetic substances can affect the living metabolism by altering enzyme activities and affecting metabolic
pathways at low concentrations. 15−20 The inhibitory properties of some antioxidant phenolic and polyphenolic
compounds like simple phenol, catechol, resorcinol, hydroquinone, pyrogallol, and quercetin were also studied
in detail. In addition, a series of active natural phenolic compounds including catechin, curcumin, dobutamine,
silymarin, and resveratrol were investigated for the inhibition of all the catalytically active mammalian CA
isozymes (CA I–CA XV). These polyphenolic compounds were effectively inhibited CA isoenzymes, with Ki
values in the range of 380 nM–12.02 µ M. In addition, the inhibitory effects of some phenolic acids including
caffeic acid, ellagic acid, ferulic acid, gallic acid, salicylic acid, syringic acid, tannic acid, p -coumaric acid,
p -hydroxybenzoic acid, 3-hydroxybenzoic acid, 3,4-dihydroxybenzoic acid, and 3,5-dihydroxybenzoic acid 12,13
on CA isoenzymes were investigated. CA plays an important role in water and ion transport and pH regulation
in the kidney, eye, central nervous system, inner ear, and other systems. To date, to the best of our knowledge,
there has been no study about the effect of rosmarinic acid on both hCA isozymes.
In the present study, we determined the inhibitory effect of rosmarinic acid as a natural phenolic
compound of plant origin on hCA I and hCA II isozymes, which is of vital importance in the living metabolism.
CA isoenzymes were purified in only one step via a Sepharose 4B-L-Tyrosine sulfanilamide affinity column from
human erythrocytes.
Rosmarinic acid is an ester of caffeic and 3,4-dihydroxyphenyllactic acids. It is generally found in a wide
range of species and plants. 21 It is especially present as a secondary metabolite in medicinal and food plants.
In addition, it is widely used in Mediterranean and Anatolian folk medicine as a culinary herb. It is also used
as a fragrant additive in cosmetic applications 22 and other applications. 23 It was reported that rosmarinic
acid had some photoprotective effects against UV and other ionizing radiations. 21 It was also reported that
rosmarinic acid had health promoting and beneficial effects. It is supposed to act as a preformed constitutively
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TOPAL and GÜLÇİN/Turk J Chem

accumulated defense compound in plants. Plant extracts that contain rosmarinic acid are a good potential
source of antioxidants for food protection and pharmaceutical applications. 23
2. Results and discussion
Rosmarinic acid is a naturally occurring phenolic compound. This natural phenolic acid is widely dispersed
in the Labitae family of herbs, which contains rosemary, basil, and perilla. CA is expressed in almost all
mammalian tissues. Known functions of CA comprise pH regulation in red blood cells and tissues, ion exchange
in the kidney, oxygen transportation between lungs and tissues, and electrical activity in the retina and nervous
system. There are different CA isozymes in many various tissues. 24,25
CA inhibitors vary according to their affinity of binding to a particular CA isoenzyme, potency for
inhibiting that isoenzyme, and physiological/biochemical properties, which can influence their tissue distribution
and activity scope. 26
Recently, it was found that CA isozymes were inhibited by several sulfamate-containing drugs 27 and a
larger scale of phenolic compounds. 12,13 Given the physiological importance of CA, the metabolic effects of
medically important drugs should receive greater attention, not only erythrocyte hCA I and II, but also the
entire array of CA isozymes. For example, in recent studies, total hepatic CA activity was shown to diminish in
the streptozotocin-induced diabetic rat. Gluconeogenesis and ureagenesis were also associated with an increase
in hepatic CA V activity. 27 There is potent evidence for overexpression of CA IX and XII in cancer, acidifying
the extracellular matrix, which is thought to promote tumor growth. Solid tumors are often hypoxic, and
expression of CA IX and XII is downregulated under these conditions. CA found within the ciliary epithelium
is associated with aqueous humor production and intraocular pressure. It is important for acid–base homeostasis,
retina metabolism, and synaptic transmission. 28 In addition, hepatic pH disequilibrium was explained in terms
of changes in CA activity. Furthermore, side effects of many drugs may be considered to result from CA
isozyme inhibition. For instance, respiratory acidosis is probably the cause of some side effects observed during
acetazolamide therapy, such as fatigue, headache, stress, and taste disorders. 5,28
Measurements of the CO 2 hydratase activity of both CA isoenzymes require specific inhibitors or
separation of the isozymes. It is difficult to study the factors and conditions that affect CA activity because
standard CA activity assays have serious limitations. Therefore, the estimation of both CA isoenzymes’ levels
in erythrocytes is complicated by the pronounced differences in enzymatic activity of both CA isoenzymes. 5
In the present study, given the importance of CA in pH regulation in most tissues, the effects of increasing
concentration of rosmarinic acid administration on hCA I and II isozymes were also examined. Thus, both CA
isoenzymes were purified by Sepharose 4B-L-Tyrosine sulfanilamide affinity chromatography (Table 1). The
purity of both isoenzymes was confirmed by SDS-PAGE (Figure). The Michaelis constant (K m ) and V max
were determined using a Lineweaver–Burk plot. All parameters were the mean of triplicate determinations
from 3 independent preparations. 29 Both isoenzymes (hCA I and II) were obtained with a yield of 57.86% and
67.17% and a specific activity of 534.88 and 3560.0 EU mg −1 proteins. At the same time, hCA I and II were
purified 76.5- and 509.3-fold, respectively (Table 1).
The phenyl fragment of phenol was found in the hydrophobic part of the hCA II active site and bound in
hCA II as a precatalytic complex. 14 Recently, our groups have analyzed the interactions between some phenols,
phenolic acids, polyphenols, antioxidant phenolic compounds, and natural polyphenol products and known
mammalian isozymes (CA I–XV). Many of these phenolic compounds have low micromolar or submicromolar
inhibition as well as the possibility of modeling isozyme selective CA isoenzyme inhibitors. In fact, the inhibition
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background of various CA isozymes with phenolic compounds is very variable, with K i values ranging from the
millimolar to the submicromolar range. 21−23 Above all, most of these natural phenolic compounds are used in
clinical, pharmaceutical, and antioxidant applications as food additives. In addition, it was recently reported
that some new benzotropone derivatives inhibited both CA isoenzymes at low micromolar levels. 30
Table 1. Purification scheme of hCA I and hCA II from human erythrocytes by Sepharose-4B-L-Tyrosine sulfanilamide
affinity chromatography (hCA: human carbonic anhydrase).

Activity
(EU/mL)

Total
volume
(mL)

Protein
(mg/mL)

Total
protein
(mg)

Total
activity

Specific
activity
(EU/mg)

Yield
(%)

Purification
fold

106

30

15.15

454.15

3180

6.99

100

1

Hemolysate
Sepharose-4B -LTyrosine
sulfanilamide
affinity
chromatography

CA I

230

8

0.43

3.44

1840

534.88

57.86

76.52

CA II

534

4

0.15

0.6

2136

3560

67.17

509.29

Figure. SDS-polyacrylamide gel electrophoresis of hCA I and II purified by Sepharose 4B-L-Tyrosine sulfanilamide
affinity gel chromatography (hCA: human carbonic anhydrase, a is hCA isoenzymes, c is hCA II isoenzymes, b is
standard proteins obtained from prestained protein molecular weight marker, 1: 85 kDa, 2: 50 kDa, 3: 35 kDa, 4: 25
kDa, 5: 20 kDa).

Rosmarinic acid was found to be sufficient for inhibition of both isoenzymes. In this respect, it was
understood from in vitro studies that both hCA isoenzymes were inhibited by rosmarinic acid (Table 2). Fifty
percent inhibitory concentrations (IC 50 ) were 8.0 × 10 −5 M for hCA I and 47.0 × 10 −5 M for hCA II.
Moreover, the K i value of rosmarinic acid was 86.0 × 10 −5 M for hCA I and 57.0 × 10 −5 M for hCA II.
Recently, in another study, IC 50 values for dantrolene sodium were 4.09 × 10 −5 M for hCA I and 3.24 ×
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10 −5 M for hCA II. 25 In the same way, both hCA isoenzymes were inhibited by melatonin up to 2 × 10 −4 M.
After the concentration of 4 × 10 −4 M, the inhibitory effect of melatonin decreased with increased melatonin
concentration. 9
Table 2. IC 50 and K i values obtained from regression analysis graphs for CA isoenzymes in the presence of different
rosmarinic acid concentrations.

Inhibition parameters
IC50
Ki
Inhibition type

hCA I (µM)
8.00
86.0
Noncompetitive

hCA II (µM)
47.0
57.0
Noncompetitive

CA inhibitors are frequently used for the treatment of different diseases including edema, epilepsy,
glaucoma, and acute mountain sickness. On the other hand, it is well known that acetazolamide is used in
treating these diseases. 29 Recently, it was demonstrated that a simple phenolic compound, such as catechol and
resorcinol, acts as a CA inhibitor. 31
Like rosmarinic acid, good inhibitory activity has been found in food bioactive compounds such as
curcumin, catechin, dobutamine, resveratrol, and silymarine for the inhibition of cytosolic hCA II. Structureactivity insight is well known for this small series of phenolic compounds. As with dobutamine, this trend is
contained when different groups are present in the para position to the phenol moiety (–OH). 14
CA I and CA II are the 2 major CA isozymes present at high concentrations in the cytosol in erythrocytes,
and CA II is the most active of all CAs. The objective of this research was to purify CA I and CA II isozymes
from human erythrocytes by Sepharose-4B affinity chromatography column chromatography and determine the
in vitro effects of rosmarinic acid on CA I and CA II isozymes.
3. Experimental
3.1. Chemicals
CNBr-activated-Sepharose 4B, rosmarinic acid, protein assay marker, and the other chemicals and reagents for
electrophoresis were obtained from Sigma (Sigma-Aldrich GmbH, Steinheim, Germany). The other chemicals
were of analytical grade and purchased from Merck.
3.2. Purification of hCA isoenzymes
At the outset, the human blood was obtained from the Atatürk University Research Hospital Blood Center.
Erythrocytes were obtained from low-speed centrifugation (1000 ×g) for 15 min by elimination of the plasma
and buffy coat. The erythrocytes were washed with physiological saline (% w/v: 0.9 NaCl) and hemolyzed with
1.5 volumes of cold water. Then intact cells and ghost were extracted at medium speed centrifugation (13,500
× g) for 30 min at low temperature (4 ◦ C). The pH of hemolysate medium was adjusted to 8.7 using solid
Trisma. Finally, pH-adjusted hemolysate was loaded to the affinity column. The affinity column was packed
with SB-L-TS resin and pre-equilibrated with Tris-HCl/Na 2 SO 4 (0.25 M/0.1 M) at pH 8.7. 32
One hundred milliliters of new prepared human erythrocyte hemolysate was applied to the affinity column
and washed with Na 2 SO 4 (22 mM), in Tris-HCl buffer solution (25 mM, pH 8.7). Both isoenzymes were eluted
with NaCl (1.0 M) in sodium phosphate buffer (25 mM, pH 6.3) and NaClO 4 (0.5 M) in sodium acetate buffer
(0.1 M, pH 5.6), respectively. Column flow rate was 20 mL h −1 . The fractions were collected in a fraction
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collector at low temperature (4 ◦ C). Absorbance of fractions at 280 nm was recorded for the determination of
protein elution by affinity chromatography. Finally, CO 2 -hydratase activity in each eluate was determined and
the enzymatically active fractions were collected. 33
3.3. Protein determination
The quantity of protein was calculated by the Bradford method. 34 For this purpose, the absorbance of the
sample was measured at 595 nm after the reaction. Bovine serum albumin (BSA) was used as a standard
protein, as described previously. 35−37
3.4. SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
Discontinuous PAGE was used under denaturing conditions after the purification of both hCA isoenzymes,
according to Laemmli’s procedure, 38 as described previously. 5 The stacking and running gels contained 3%
(w/v) and 10% (w/v) acrylamide, respectively, and 0.1% (w/v) SDS. The electrode buffer was Tris (0.25
M)/glycine (2 M), pH 8.3.
The buffer solution was prepared by mixing Tris-HCl (0.65 mL, 1 M, pH 6.8), SDS (3 mL, w/v: 10%),
neat glycerol (1 mL), bromphenol blue (1 mL, w/v: 0.1%), β -mercaptoethanol (0.5 mL), and water (3.85 mL).
An aliquot of enzyme (20 µ g) was added to the sample buffer solution (50 µ L) and the mixture was heated in
a water bath (100 ◦ C) for 3 min and cooled.
Both isozymes’ samples were loaded into each space of the stacking gel. Initially, an electric potential of
80 V was applied until the bromphenol dye reached the running gel. Then it was increased to 200 V over 3–4
h. The gel was kept in Coomassie Brilliant Blue R-250 (w/v: 0.1%) reagent in methyl alcohol (v/v: 50%) and
acetic acid (v/v: 10%) and distained with methanol/acetic acid for 90 min. The electrophoretic zymogram was
photographed (Figure).
3.5. CA isozymes’ inhibition effects
The effects of increasing concentrations of rosmarinic acid on hCA I and hCA II isoenzymes were determined
colorimetrically using CO 2 hydration. 39 Briefly, both CA isozymes’ samples were added to 4.2 mL (final volume)
of incubation mixture containing 1 mL of Veronal buffer (0.025 M, pH 8.2), bromothymol blue (0.1 mL, w/v:
0.04%), and saturated CO 2 solution in water (2.5 mL). Both CA isozymes’ activity was measured by colorimetric
method considering the required time for changing of pH from 8.2 to 6.3. One enzyme unit (EU) for CO 2 hydratase activity of both CA isozymes was calculated by using the equation (to – tc / to ) , where to and tc are
the times for pH change of the nonenzymatic and enzymatic reactions, respectively.
3.6. Statistical analysis
The data are reported as the mean ± SD and were analyzed by SPSS (version 17.0). Significant differences
between the means were determined by Duncan’s multiple range test. P < 0.05 was considered significant.
Each experiment was performed in triplicate.
4. Conclusion
Rosmarinic acid is a natural phenol antioxidant carboxylic acid and is found in many plant families. It has 4
phenolic –OH functional groups in their aromatic scaffold. It effectively inhibited both hCA isozymes because
900
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of its 4 functional phenolic –OH groups. These findings clearly indicated that phenolic compounds are another
class of possible hCA inhibitors in addition to other putative hCA inhibitors such as sulfonamides, sulfamates,
and sulfamides. Rosmarinic acid, as a natural phenolic compound, showed effectiveness in inhibition of both
hCA isoenzymes’ activities in the low micromolar range. These results indicate that compounds with substituted
phenolic may be used as potent hCA isoenzyme inhibitors.
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